PorMedTec Co., Ltd

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

PorMedTec Co., Ltd - overview

Established

2017

Location

-, -, Japan

Primary Industry

Biotechnology

About

Based in Kawasaki, Japan, and founded in 2017 by its Chief Scientist, Hiroshi Nagashima, and CEO, Board director, Genjiro Miwa as a spin-off venture at the Meiji University International Institute for Bio-Resource Research (MUIIBR). PorMedTec Co. , Ltd. , operates as a health care technology company that provides transplantable organs, tissues, and cells for the treatment of patients.


In March 2022, PorMedTec Co. , Ltd.  raised JPY 40 million from a new investor, IDDM Network, in an unspecified round. The company offers a bioengineering platform that includes genetic modifications of porcine somatic and embryonic cells for the production of cloned pigs.


The company has developed a unique U-iR (Uterectomy Isolated Rearing) system to produce hygienic standardized pigs for xenotransplantation. The company has also created human-pig hybrid organs that can be used for transplantation into human patients. The company plans to use the March funding for the acceleration of bioartificial islet transplantation technology.


Current Investors

Threem Holding , Global Brain

Primary Industry

Biotechnology

Sub Industries

Biotechnology

Website

www.pormedtec.com

Verticals

Manufacturing

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

PorMedTec Co., Ltd - employee data

Blurred Background

Want to see Employee Count?

Request a demo for full access to this profile.

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.